Compare Futu Holdings Ltd (FUTU) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Eli Lilly And Co — how do they compare? Futu Holdings Ltd trades at $110.71 (market cap $15.25B), while Eli Lilly And Co trades at $1,163.51 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 68.2× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Eli Lilly And Co for 93 Days on average.
| FUTU | LLY | |
|---|---|---|
Market Cap | $15.25B | $1.04T |
Volume | 812,567 | 3,064,878 |
Sector | Financials | Health |
52-Week High | $199.04 | $1.28K |
52-Week Low | $89.76 | $799.57 |
Typical Hold Time | 34 Days | 93 Days |
Enterprise Value | $15.59B | $1.09T |
Dividend Yield | 2.39% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings trades at $109.68, down 3.12% today amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 10.86, net income margin of 42.92%, and robust revenue growth from $13.6B in 2024 to $22.85B in 2025. Recent news includes Moomoo's partnership with X's Cashtag program and a class action lawsuit deadline on August 25, 2026.
The outlook is mixed: strong profitability and analyst upside targets near 33% contrast with legal risks and technical weakness. Key risks include lawsuit outcomes and market volatility, while growth drivers are overseas expansion and trading platform adoption. Investors face a balance of high returns potential against significant headline risks.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.
Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
